Literature DB >> 31601387

A Contemporary Definition of Periprocedural Myocardial Injury After Percutaneous Coronary Intervention of Chronic Total Occlusions.

Georg Goliasch1, Max-Paul Winter1, Mohamed Ayoub2, Philipp E Bartko1, Catherine Gebhard1, Kambis Mashayekhi2, Miroslaw Ferenc2, Heinz Joachim Buettner2, Christian Hengstenberg1, Franz-Josef Neumann2, Aurel Toma3.   

Abstract

OBJECTIVES: The aim of this study was to assess the prognostic impact of post-procedural troponin T increase and mortality in patients undergoing percutaneous coronary intervention (PCI) for chronic total occlusion (CTO) to define the threshold at which procedure-related myocardial injury drives mortality.
BACKGROUND: Coronary CTO recanalization represents the most technically challenging PCI. The complexity harbors a significant increased risk for complications with CTO PCI with compared with non-CTO PCI. However, there are evidenced biomarker cutoff levels that help identify those patients at risk for unfavorable clinical outcomes.
METHODS: A total of 3,712 consecutive patients undergoing PCI for at least 1 CTO lesion were enrolled, and comprehensive troponin T measurements were performed 6, 8, and 24 h after the procedure. All-cause mortality was defined as the primary study endpoint.
RESULTS: Using spline curve analysis, a more than 18-fold increase of troponin above the upper reference limit was significantly associated with mortality. In a Cox regression analysis, the crude hazard ratio was 2.32 (95% confidence interval: 1.83 to 2.93; p < 0.001) for a ≥18-fold increase compared with patients with post-procedural troponin increase <18-fold of the upper reference limit. Results remained virtually unchanged after bootstrap- or clinical confounder-based adjustment.
CONCLUSIONS: This large-scale outcome study demonstrates for the first time the prognostic value of post-procedural troponin T elevation after PCI in patients with CTOs. A threshold was defined for procedure-related myocardial injury in patients with CTOs to differentiate them from those without CTOs that may help guide post-procedural clinical care in this high-risk patient population.
Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CTO; PCI; chronic total occlusion; coronary artery disease

Year:  2019        PMID: 31601387     DOI: 10.1016/j.jcin.2019.06.053

Source DB:  PubMed          Journal:  JACC Cardiovasc Interv        ISSN: 1936-8798            Impact factor:   11.195


  6 in total

1.  Effects and mechanisms of glucose-insulin-potassium on post-procedural myocardial injury after percutaneous coronary intervention.

Authors:  Yi-Dan Hao; Peng Hao; Zheng Wang; Ying-Xin Zhao; Zhi-Ming Zhou; Yu-Yang Liu; De-An Jia; Hong-Ya Han; Bin Hu; Hua Shen; Fei Gao; Guo-Zhong Pan; Zhen-Feng Guo; Shi-Wei Yang; Yu-Jie Zhou
Journal:  J Geriatr Cardiol       Date:  2020-09-28       Impact factor: 3.327

Review 2.  Pitavastatin: Coronary Atherosclerotic Plaques Changes and Cardiovascular Prevention.

Authors:  Francesco Fici; Gokhan Faikoglu; Bahar Arican Tarim; Nicolas Roberto Robles; Kostas Tsioufis; Guido Grassi; Barış Gungor
Journal:  High Blood Press Cardiovasc Prev       Date:  2022-01-22

3.  Serum lipoprotein(a) and risk of periprocedural myocardial injury in patients undergoing percutaneous coronary intervention.

Authors:  Zhuoshan Huang; Xing Shui; Yesheng Ling; Linli Zhou; Wenqi Shi; Yanting Luo; Suhua Li; Jieming Zhu; Shujie Yu; Jinlai Liu
Journal:  Clin Cardiol       Date:  2020-12-02       Impact factor: 2.882

4.  Postprocedural Troponin Elevation and Mortality After Transcatheter Aortic Valve Implantation.

Authors:  Matthias Schindler; Florin Stöckli; Rico Brütsch; Philipp Jakob; Erik Holy; Jonathan Michel; Robert Manka; Paul Vogt; Christian Templin; Markus Kasel; Frank Ruschitzka; Barbara E Stähli
Journal:  J Am Heart Assoc       Date:  2021-10-29       Impact factor: 5.501

5.  Contemporary Strategies and Outcomes of Dedicated Chronic Total Occlusion Percutaneous Coronary Intervention Programs: A Prospective Multicentre Registry.

Authors:  Maarten Vanhaverbeke; Ward Eertmans; Wouter Holvoet; Ief Hendrickx; Keir McCutcheon; Christophe Dubois; Joseph Dens; Johan Bennett
Journal:  J Interv Cardiol       Date:  2021-12-07       Impact factor: 2.279

6.  Effect of trimetazidine on incidence of major adverse cardiac events in coronary artery disease patients undergoing percutaneous coronary intervention: A protocol for systematic review and meta-analysis.

Authors:  Kun Zhu; Yu-Shui Zheng; Yong Fang
Journal:  Medicine (Baltimore)       Date:  2020-10-30       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.